Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

ation of SEROQUEL was administered twice-daily and escalated from 50 mg/day to 400 mg/day over a five-day period. The most common adverse events seen in the active treatment groups during the trial were somnolence and dizziness. The incidences of adverse events leading to discontinuation were low: 5.3%, 2.7%, and 2.5% in the SEROQUEL XR 400, 600, 800 mg/day groups; 4.9% in the immediate release SEROQUEL group; and 2.5% in the placebo group. Individual extrapyramidal symptoms (EPS)-related adverse events occurred in three patients or less in all treatment groups.(1,2)

    (+) Schizophrenic symptomatology measured on 30-item Positive and Negative

        Syndrome Scale (PANSS) scale. Each symptom was rated on a severity

        scale from 1-7. PANSS positive (7 items), negative (7 items), and

        general psychopathology (16 items) subscale scores were summarized to

        give the PANSS total score.(3)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate in Patients with Acute Schizophrenia

This first analysis of Study 132 evaluated the efficacy of SEROQUEL XR versus placebo in patients with schizophrenia. The primary endpoint was the change from baseline to Day 42 in PANSS total score.(1)

After six weeks, the mean PANSS total score decreased significantly with SEROQUEL XR (400 mg: -24.8, p < 0.05; 600 mg: -30.9, p < 0.001; 800 mg: -31.3, p < 0.001) compared with placebo (-18.8). In addition, PANSS response rates for SEROQUEL XR (all doses) were significantly higher than for placebo (p < 0.05).(1)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate across Symptom Domains in Schizophrenia

In this second analysis of Study 132, the efficacy of SEROQUEL XR was evaluated across a broad range of symptoms in schizophrenia, including positive and negative symptoms as well as symptoms of general psychopathology, aggr
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/4/2015)... MENLO PARK, Calif. , Sept. 4, 2015 ... and the "Company"), a biopharmaceutical company focused on the ... its financial results for the fiscal year ending June ... highlights and expected near-term milestones. DelMar,s ... and live webcast for investors, analysts and other interested ...
(Date:9/3/2015)... -- Cipla, a global pharmaceutical company which uses technology and ... today announced that its UK arm, Cipla EU has ... InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction ... $550 million and will be an all cash transaction. ... million for the year ended Dec 2014 and over ...
(Date:9/3/2015)... Report Details What can be expected from ... grow at the fastest rates? Visiongain,s brand new report ... opportunities and prospects there. Our 205-page report ... lucrative areas in the industry and the future market ... at overall world market and regional level. You will ...
Breaking Medicine Technology:DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First and Last ... funding for sidewalks, bike paths, and other vital supports severely limit access to public ... billions of dollars to expand public transit, there’s very little support for safe and ...
(Date:9/4/2015)... ... ... IVF New England, one of the largest and most successful fertility centers ... for women who wish to learn more about their fertility and egg freezing. , ... Elm Street, Manchester, NH from 6PM to 7PM , This hip, casual and informative ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today ... meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. ... in the consumer goods industry, it can be difficult for companies to navigate, ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Keeping mold ... and around the home is quite common. Mold can grow anywhere - on carpet, ... leaking pipes. Checking for excessive moisture and water in the home is key to ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL who ... the Ironman World Championships in Kona on October 10th. , Mike is running the ... (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
Breaking Medicine News(10 mins):Health News:Missed Connections in Metro Denver Transit 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... solid reputation within industry , , HOFFMAN ESTATES, ... Spine, Inc. announced today that it has appointed Todd P. ... Fanning has held senior sales and marketing positions at well ... orthopaedic industries, including Spinal Concepts (now part of Zimmer ...
... EHR/PM System to Help Physicians, Organization Deliver on Its ... DALLAS, June 9 iMedica Corporation ... physician practices, announced today that after more than two ... Organization of the University Medical Center at Princeton ...
... by Miley Cyrus at the 20th Annual A Time For ... Glaser Pediatric AIDS Foundation , , LOS ANGELES, June ... at the 20th annual A Time For Heroes Family Picnic, ... Elizabeth Glaser Pediatric AIDS Foundation. More than 80 of Hollywood,s ...
... Denise Gott Agrees that Everyone Needs Protection for Longer-Lasting ... , KIRKLAND, Wash., June 9 The traditionally conservative ... Congress on health reform, according to one insurance leader, ... Kennedy (D-MA) for his crusading efforts. "He sees more ...
... ... (MARS) has received CE Mark approval for treating patients with peripheral aneurysms. Product rollout ... ... received CE Mark approval for the commercial sale of its Multilayer Aneurysm Repair System. ...
... ... Global will offer a 22% Recession Price Rollback on their 22, Dell Touch Screen Monitor. ... value. , ... June 9, 2009 -- Today,s market is a very discerning. Smaller budgets, less tax revenues ...
Cached Medicine News:Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 2Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 3Health News:Celebrities Come Together to Fight Pediatric AIDS 2Health News:Celebrities Come Together to Fight Pediatric AIDS 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 2Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 4Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2Health News:Tech Global Price Rollback on their 22" Dell Touch Screen Monitor 2
... The 5548 is our High Penetration Steered ... ranging from 3 to 8 MHz. ... offering Pure Harmonic Detection with 4 different ... or deeper vessels. The high color and ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency "I shaped convex intraoperative transducer. The UST-995-7.5 nestles comfortably between your index and middle fingers so that you can palpate organs while scanning...
Super High Density, multi frequency Side Fire "T intraoperative transducer. A narrower field of view is this transducers benefit for when scanning in smaller abdomens or in tighter spaces....
Medicine Products: